On May 22, 2024, China Reform Health and Beijing tricision Biotech Co., Ltd. (tricision) signed a Strategic Cooperation Agreement in Beijing—a milestone collaboration that marks a significant acceleration in the translation of innovative drug candidates from clinical trials to market. The partnership is expected to drive growth across the biopharmaceutical value chain and contribute to a new, more dynamic ecosystem for the industry.

Leveraging the full resources of the "China Reform Biopharmaceutical" industrial synergy platform, China Reform Health will apply its expertise in healthcare, medical insurance, and pharmaceutical data—combined with Artificial Intelligence (AI) and big data—to provide pharmaceutical companies with end-to-end life-cycle data services. These include clinical trial support, Real-World Evidence (RWE) generation, regulatory filing and market access, digital production, supply chain optimization, and precision marketing. The goal is to accelerate the R&D process, improve success rates, and create measurable value for partners.

For its part, tricision has built a strong reputation as a high-tech enterprise focused on tumor immunotherapy and gene editing. Its advanced cellular therapy platform has successfully activated patients' own immune systems to target and eliminate tumor cells, delivering outcomes that offer new hope for patients with refractory cancers.

The collaboration brings together the complementary strengths of China Reform Health, China Reform Fund, and China Reform Securities to provide tricision with integrated, "one-stop" value-added services across investment, R&D, operations, marketing, production, and service. This comprehensive support model is designed to accelerate the development of cutting-edge therapies and ensure they reach patients faster.

Beyond supporting tricision's immediate programs, the partnership also aims to identify and invest in early-stage, high-quality opportunities across the biopharmaceutical supply chain. By leveraging the collective resources and expertise of the China Reform ecosystem, the collaboration is positioned to drive scalable industrial growth and help shape the future of biopharmaceutical innovation in China.